Cargando…

Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib

Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic fusion protein BCR–Abl1 are used successfully in targeted therapy of chronic myeloid leukemia (CML). Such inhibitors provided the first proof of concept that kinase inhibition can succeed in a clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oruganti, Baswanth, Lindahl, Erik, Yang, Jingmei, Amiri, Wahid, Rahimullah, Rezwan, Friedman, Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386466/ https://www.ncbi.nlm.nih.gov/pubmed/35809644 http://dx.doi.org/10.1016/j.jbc.2022.102238

Ejemplares similares

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)

Activation of Abl1 Kinase Explored Using Well-Tempered Metadynamics Simulations on an Essential Dynamics Sampled Path
por: Oruganti, Baswanth, et al.
Publicado: (2021)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2006)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2019)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

Cobind: quantitative analysis of the genomic overlaps
por: Ma, Tao, et al.
Publicado: (2023)

Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Evidence of widespread, independent sequence signature for transcription factor cobinding
por: Zhou, Manqi, et al.
Publicado: (2021)

Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach
por: Shukla, Suneet, et al.
Publicado: (2014)

Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
por: Genthon, Alexis, et al.
Publicado: (2020)

Bcr-Abl: one kinase, two isoforms, two diseases
por: Reckel, Sina, et al.
Publicado: (2017)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ
por: Shang, Jinsai, et al.
Publicado: (2018)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
por: Hughes, T P, et al.
Publicado: (2017)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation
por: Reinwald, Mark, et al.
Publicado: (2014)

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
por: Grebien, Florian, et al.
Publicado: (2011)

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
por: Mauro, Michael J., et al.
Publicado: (2023)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
por: Huo, Li, et al.
Publicado: (2023)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
por: Eadie, Laura N., et al.
Publicado: (2018)

On the possibility to accelerate the thermal isomerizations of overcrowded alkene-based rotary molecular motors with electron-donating or electron-withdrawing substituents
por: Oruganti, Baswanth, et al.
Publicado: (2016)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase
por: Iacob, Roxana E., et al.
Publicado: (2011)

Atomic view of the energy landscape in the allosteric regulation of Abl kinase
por: Saleh, Tamjeed, et al.
Publicado: (2017)

Myristoyl’s dual role in allosterically regulating and localizing Abl kinase
por: de Buhr, Svenja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nvegbrv2d0qj5krgk45gv8nhgq